Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

HROW

Harrow Inc

Dec 08 • 04:00PM ET

9.79

Dollar change +0.15
Percentage change 1.56	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	14.54%	Shs Outstand	35.12M	Perf Week	5.16%
Market Cap	343.82M	Forward P/E	62.49	EPS next Y	0.16	Insider Trans	1.56%	Shs Float	30.01M	Perf Month	-24.28%
Income	-14.21M	PEG	-	EPS next Q	-0.04	Inst Own	70.96%	Short Float / Ratio	20.35% / 8.90	Perf Quarter	-41.06%
Sales	114.17M	P/S	3.01	EPS this Y	-1.31%	Inst Trans	-4.64%	Short Interest	6.11M	Perf Half Y	-51.68%
Book/sh	2.16	P/B	4.54	EPS next Y	130.32%	ROA	-7.38%	Target Price	28.13	Perf Year	-19.02%
Cash/sh	2.10	P/C	4.65	EPS next 5Y	15.00%	ROE	-36.92%	52W Range	7.60 - 28.25	Perf YTD	-33.67%
Dividend	-	P/FCF	-	EPS past 5Y	3.03%	ROI	-5.37%	52W High	-65.35%	Beta	0.41
Dividend %	-	Quick Ratio	5.33	Sales past 5Y	28.85%	Gross Margin	69.78%	52W Low	28.82%	ATR	0.60
Employees	217	Current Ratio	5.80	Sales Q/Q	50.13%	Oper. Margin	3.09%	RSI (14)	41.51	Volatility	3.53% 6.50%
Optionable	Yes	Debt/Eq	2.50	EPS Q/Q	45.77%	Profit Margin	-12.44%	Rel Volume	0.70	Prev Close	9.64
Shortable	Yes	LT Debt/Eq	2.49	Earnings	Nov 13 AMC	Payout	-	Avg Volume	686.02K	Price	9.79
Recom	1.00	SMA20	1.16%	SMA50	-21.12%	SMA200	-44.97%	Volume	483,386	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
08:00AM	Loading…
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
02:56PM	Loading…
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)
04:04PM	Harrow Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq (Business Wire)
Jul-05-23 06:15PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know (Zacks)
Jun-29-23 06:15PM	Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 06:15PM	Harrow Health (HROW) Flat As Market Sinks: What You Should Know (Zacks)
Jun-16-23 06:00PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
May-17-23 08:00AM	Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 (Business Wire)
11:57AM	Loading…
May-16-23 11:57AM	Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 11:21AM	Analysts Initiate Coverage: 5 Stocks for Higher Returns (Zacks) -5.22%
May-12-23 01:48PM	Why Shares of Harrow Health Are Slumping Friday (Motley Fool) -18.58%
06:26AM	Q1 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:15PM	Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Harrow: Q1 Earnings Snapshot (AP Finance)
04:01PM	Harrow Announces First Quarter 2023 Financial Results (Business Wire)
May-08-23 12:07PM	Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing? (Zacks)
May-04-23 08:00AM	Harrow to Launch FDA-Approved IHEEZO at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
May-02-23 04:42PM	Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May (Zacks)
09:40AM	Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. (Business Wire)
May-01-23 08:50AM	Here's Why Momentum in Harrow (HROW) Should Keep going (Zacks)
Apr-28-23 06:00PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
08:00AM	Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-24-23 08:43AM	Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:09AM	Bull Of The Day: Harrow Health (HROW) (Zacks)
Apr-20-23 08:31AM	5 Small Hidden Gems to Pick From a Rangebound Wall Street (Zacks)
Apr-19-23 06:15PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
08:31AM	Zacks.com featured highlights include Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings (Zacks)
Apr-18-23 06:24AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)
Apr-14-23 08:50AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Apr-13-23 06:15PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-12-23 09:40AM	Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year? (Zacks)
Apr-09-23 04:04PM	A New Roster of Top Stock-Fund Managers (The Wall Street Journal)
Apr-05-23 09:34AM	4 Medical Stocks to Buy as Rate Hike Cycle Nears End (Zacks)
Apr-04-23 05:37AM	Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus (Zacks)
Apr-03-23 06:53AM	5 Stocks With Recent Price Strength Amid March Rally (Zacks)
Mar-29-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Mar-28-23 02:59PM	B. Riley Leads Financing to Support Harrow Health Acquisition (PR Newswire)
07:00AM	Harrow Announces New $100 Million Secured Credit Facility with Oaktree (Business Wire)
Mar-27-23 08:51AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Call Transcript (Insider Monkey) +16.50%
Mar-24-23 05:42AM	Q4 2022 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM	Harrow Announces Fourth Quarter and Year-End 2022 Financial Results (Business Wire)
Mar-13-23 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% (Business Wire)
Mar-06-23 08:00AM	Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance (Business Wire)
Mar-02-23 08:00AM	Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 (Business Wire)
Feb-16-23 06:42AM	Is Harrow Health (HROW) an Undervalued Stock? (Insider Monkey) +5.41%
Feb-15-23 07:00AM	Harrow Launches Next-Generation Compounded Atropine Formulations (Business Wire)
Feb-03-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +8.29%
Feb-02-23 06:30AM	Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 (Business Wire) +6.53%
Jan-23-23 07:00AM	Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products (Business Wire)
Jan-21-23 07:33AM	Investing in Harrow Health (NASDAQ:HROW) five years ago would have delivered you a 752% gain (Simply Wall St.)
Jan-18-23 08:50AM	Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why (Zacks)
Jan-05-23 07:00AM	Harrow Announces Availability of Fortisite Formulations for In-Office Use (Business Wire)
Dec-25-22 07:24AM	Trade Alert: The CEO & Chairman of the Board Of Harrow Health, Inc. (NASDAQ:HROW), Mark Baum, Has Just Spent US$335k Buying 1.8% More Shares (Simply Wall St.)
Dec-21-22 09:21AM	Melt Pharmaceuticals MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study (Business Wire) +10.57%
Dec-16-22 07:00AM	Harrow Secures Capital to Close Recently Announced Acquisition (Business Wire)
Dec-14-22 03:24PM	Harrow Health inks $175 million deal for the rights to five medications (American City Business Journals) +15.05%
09:41AM	Harrow Health Acquires Rights To Novartis' Five Approved Ophthalmic Products (Benzinga)
06:32AM	Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and "BB" Rating from Egan-Jones (Business Wire)
06:31AM	Harrow Prices $25 Million Offering (Business Wire)
06:30AM	Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® (Business Wire)
Nov-30-22 08:00AM	Harrow and iOR Partners Expand National Product Supply Agreement (Business Wire)
Nov-16-22 05:06AM	Harrow Health Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -5.60%
Nov-14-22 04:05PM	Harrow Announces Third Quarter 2022 Financial Results (Business Wire)
Nov-10-22 08:00AM	Harrow Launches Atropine.com (Business Wire)
Oct-28-22 08:00AM	Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022 (Business Wire)
Oct-27-22 08:00AM	Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300 (Business Wire)
Oct-13-22 09:35AM	Harrow Health, Inc. (NASDAQ:HROW) has caught the attention of institutional investors who hold a sizeable 48% stake (Simply Wall St.)
Oct-06-22 03:23PM	Harrow Health sells part of company for up to $10.5 million (American City Business Journals)
Oct-05-22 05:35PM	Harrow Sells Non-Ophthalmic Compounding Business (Business Wire)
Sep-29-22 07:00AM	ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation (Business Wire) +16.25%
Sep-28-22 07:09AM	FDA Approves First Branded Ocular Anesthetic In Almost 14 Years (Benzinga)
Sep-27-22 01:50PM	Harrow Announces U.S. FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia (Business Wire) +27.86%
Sep-21-22 06:01PM	Melt Pharmaceuticals files for IPO (MarketWatch)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAUM MARK L	Chief Executive Officer	Nov 16	Buy	8.11	7,500	60,825	2,022,961	Nov 16 04:45 PM
Opaleye Management Inc.	10% Owner	Nov 15	Buy	8.03	25,000	200,735	3,645,000	Nov 16 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 20	Buy	14.49	5,983	86,710	3,620,000	Sep 20 06:39 PM
Opaleye Management Inc.	10% Owner	Sep 19	Buy	14.65	14,017	205,366	3,614,017	Sep 20 06:39 PM
Makary Martin A.	Director	Aug 14	Buy	16.92	20,000	338,400	45,000	Aug 15 07:30 AM
BAUM MARK L	Chief Executive Officer	Aug 14	Buy	17.05	5,800	98,890	2,015,461	Aug 15 07:30 AM
BAUM MARK L	Chief Executive Officer	Apr 03	Option Exercise	8.99	180,000	1,618,200	1,664,962	Apr 04 07:54 PM
BOLL ANDREW R.	Chief Financial Officer	Mar 31	Option Exercise	6.00	90,000	540,000	358,461	Apr 04 07:50 PM
BAUM MARK L	Chief Executive Officer	Dec 22	Buy	13.39	25,000	334,750	1,432,141	Dec 23 07:03 AM
BOLL ANDREW R.	Chief Financial Officer	Dec 22	Buy	13.54	2,500	33,850	255,063	Dec 23 07:02 AM
Van Horn R. Lawrence	Director	Dec 22	Buy	13.42	1,860	24,961	1,860	Dec 23 07:00 AM
Makary Martin A.	Director	Dec 21	Buy	13.37	25,000	334,250	25,000	Dec 23 07:01 AM
Opaleye Management Inc.	10% Owner	Dec 14	Buy	10.52	431,183	4,536,045	3,600,000	Dec 14 04:05 PM

Open in Screener

TCON

TRACON Pharmaceuticals Inc

Dec 08 • 04:00PM ET

0.1883

Dollar change -0.0117
Percentage change -5.85	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

TCON TRACON Pharmaceuticals Inc daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	15.21%	Shs Outstand	31.14M	Perf Week	-7.01%
Market Cap	5.86M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	0.00%	Shs Float	26.41M	Perf Month	18.80%
Income	-11.02M	PEG	-	EPS next Q	-0.10	Inst Own	29.64%	Short Float / Ratio	7.62% / 0.47	Perf Quarter	-14.41%
Sales	9.00M	P/S	0.65	EPS this Y	59.95%	Inst Trans	-0.06%	Short Interest	2.01M	Perf Half Y	-68.14%
Book/sh	-0.10	P/B	-	EPS next Y	10.18%	ROA	-75.82%	Target Price	4.00	Perf Year	-86.65%
Cash/sh	0.25	P/C	0.76	EPS next 5Y	-	ROE	-1277.01%	52W Range	0.13 - 2.19	Perf YTD	-87.36%
Dividend	-	P/FCF	-	EPS past 5Y	34.33%	ROI	-	52W High	-91.40%	Beta	1.00
Dividend %	-	Quick Ratio	0.71	Sales past 5Y	-53.15%	Gross Margin	99.83%	52W Low	50.04%	ATR	0.03
Employees	18	Current Ratio	0.71	Sales Q/Q	-	Oper. Margin	-145.97%	RSI (14)	49.65	Volatility	10.34% 17.16%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	197.43%	Profit Margin	-122.49%	Rel Volume	0.29	Prev Close	0.20
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 09 AMC	Payout	-	Avg Volume	4.31M	Price	0.19
Recom	1.67	SMA20	-2.07%	SMA50	7.85%	SMA200	-69.84%	Volume	1,242,176	Change	-5.85%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Upgrade	BTIG Research	Neutral → Buy	$14
Feb-10-21	Initiated	Maxim Group	Buy	$24
Dec-23-19	Reiterated	H.C. Wainwright	Buy	$15 → $18
Mar-01-19	Reiterated	Needham	Buy	$7
Jun-13-17	Reiterated	Stifel	Buy	$14 → $6
Dec-21-16	Initiated	Jefferies	Buy	$10
Feb-01-16	Resumed	Oppenheimer	Outperform
Jul-29-15	Initiated	ROTH Capital	Buy	$18
Mar-02-15	Reiterated	Stifel	Buy	$16 → $20
Mar-02-15	Reiterated	Oppenheimer	Outperform	$22 → $26
Feb-24-15	Initiated	Stifel	Buy	$16
Feb-24-15	Initiated	Oppenheimer	Outperform	$22

Show Previous Ratings

Nov-21-23 07:55AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today? (InvestorPlace) +25.07%
07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Nov-20-23 08:00AM	TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment (GlobeNewswire)
Nov-13-23 09:29AM	Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today? (InvestorPlace) -7.08%
Nov-12-23 08:47AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:45AM	Loading…
Nov-10-23 07:45AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today? (InvestorPlace) +43.94%
Nov-09-23 04:58PM	Tracon: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 04:02PM	TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 (GlobeNewswire) +11.35%
Sep-18-23 08:00AM	TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned (GlobeNewswire)
Sep-05-23 04:02PM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Aug-15-23 08:43AM	Q2 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.95%
Aug-14-23 07:00PM	Tracon: Q2 Earnings Snapshot (Associated Press Finance) -9.66%
04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Aug-02-23 04:05PM	TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023 (GlobeNewswire) +14.06%
Jul-11-23 08:00AM	TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma (GlobeNewswire) +5.52%
Jun-20-23 08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Jun-16-23 08:00AM	TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference (GlobeNewswire)
Jun-15-23 08:00AM	TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma (GlobeNewswire) -5.91%
Jun-02-23 08:00AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire) +7.93%
May-30-23 08:00AM	TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 11:24AM	Q1 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.14%
May-10-23 04:38PM	Tracon: Q1 Earnings Snapshot (AP Finance)
04:02PM	TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-23 04:02PM	TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 (GlobeNewswire) +5.19%
Apr-25-23 07:41AM	TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab (GlobeNewswire) -46.63%
Apr-06-23 08:30AM	Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update (GlobeNewswire) +6.19%
Mar-14-23 12:00PM	Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.16%
Mar-10-23 02:26AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript (Insider Monkey) +8.33%
05:49AM	Loading…
Mar-09-23 05:49AM	Q4 2022 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -8.00%
Feb-28-23 04:02PM	TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023 (GlobeNewswire)
Jan-20-23 06:55AM	Daily Vickers Top Buyers & Sellers for 01/20/2023 (Argus Research)
Jan-10-23 08:30AM	Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update (GlobeNewswire)
Dec-27-22 08:00AM	TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023 (GlobeNewswire) +10.34%
Dec-14-22 11:29AM	TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Nov-21-22 08:00AM	TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma (GlobeNewswire)
Nov-14-22 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +9.03%
Oct-31-22 08:00AM	TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022 (GlobeNewswire)
Oct-06-22 08:30AM	Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update (GlobeNewswire) +6.63%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned (GlobeNewswire)
Sep-14-22 08:00AM	TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS (GlobeNewswire)
Sep-07-22 08:00AM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-06-22 08:00AM	TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital (GlobeNewswire) -5.53%
Aug-29-22 08:00PM	US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (Business Wire)
11:45AM	TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Aug-10-22 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.11%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-08-22 08:00AM	TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Jul-27-22 08:05AM	TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022 (GlobeNewswire) +6.32%
Jul-26-22 08:05AM	TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter (GlobeNewswire)
Jun-02-22 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-16-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +15.57%
May-11-22 04:02PM	TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-22 08:05AM	TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022 (GlobeNewswire)
Apr-19-22 08:05AM	TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K. (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-23-22 08:05AM	TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire) +9.16%
Mar-15-22 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-22 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -6.85%
Mar-10-22 08:05AM	TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol (GlobeNewswire) +18.22%
Mar-04-22 08:05AM	TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022 (GlobeNewswire)
Feb-02-22 08:05AM	TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute (GlobeNewswire)
Jan-05-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire) -9.25%
Dec-27-21 08:00AM	TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial (GlobeNewswire) -20.16%
Nov-29-21 08:05AM	TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China (GlobeNewswire)
Nov-11-21 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference (GlobeNewswire)
Nov-03-21 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-21 08:05AM	TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021 (GlobeNewswire)
Oct-13-21 08:00AM	TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors (GlobeNewswire)
Oct-11-21 01:27PM	TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications (Benzinga) +7.96%
08:00AM	TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001 (GlobeNewswire)
Sep-13-21 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (GlobeNewswire)
Sep-07-21 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
07:29AM	TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments (Benzinga)
Sep-02-21 08:05AM	TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference (GlobeNewswire) +6.04%
Aug-11-21 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-21 08:05AM	TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-03-21 08:05AM	TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) -10.05%
Jul-28-21 08:05AM	TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021 (GlobeNewswire)
Jul-21-21 10:30PM	TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million (GlobeNewswire)
05:27PM	TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Jul-20-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award (GlobeNewswire) +5.10%
Jun-30-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award (GlobeNewswire)
Jun-29-21 08:05AM	TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma (GlobeNewswire)
Jun-28-21 01:04PM	Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy? (Insider Monkey)
Jun-18-21 10:08AM	3 Strong Buy Stocks Under $10 With Over 100% Upside Potential (TipRanks) +10.17%
Jun-04-21 09:01AM	TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting (GlobeNewswire)
Jun-01-21 08:05AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
May-25-21 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-20-21 08:05AM	TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting (GlobeNewswire)
May-05-21 04:03PM	TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
02:45PM	TRACON Pharmaceuticals, Inc. to Host Earnings Call (ACCESSWIRE)
08:25AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (ACCESSWIRE)
May-03-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics (GlobeNewswire)
Apr-28-21 08:05AM	TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021 (GlobeNewswire)
Apr-26-21 08:00AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire) +5.31%

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THEUER CHARLES	President and CEO	Apr 27	Buy	0.75	47,000	35,250	399,417	Apr 28 06:00 AM
THEUER CHARLES	President and CEO	Apr 26	Buy	0.66	3,999	2,639	352,417	Apr 28 06:00 AM
Opaleye Management Inc.	10% Owner	Mar 09	Buy	1.38	174,508	240,821	4,324,508	Mar 13 04:05 PM
THEUER CHARLES	President and CEO	Mar 01	Buy	1.52	4,800	7,296	344,918	Mar 02 06:24 AM
THEUER CHARLES	President and CEO	Feb 28	Buy	1.52	200	304	340,118	Mar 02 06:24 AM
THEUER CHARLES	President and CEO	Jan 18	Buy	1.62	6,800	11,016	339,918	Jan 19 06:05 AM
Brown Scott B.	Chief Financial Officer	Dec 29	Buy	1.49	3,500	5,215	21,628	Jan 03 06:00 AM
LARUE WILLIAM R	Director	Dec 21	Sale	1.26	120	151	7,763	Jan 19 06:00 AM
Opaleye Management Inc.	10% Owner	Dec 14	Buy	1.25	167,500	209,876	4,150,000	Dec 16 05:03 PM
THEUER CHARLES	President and CEO	Dec 14	Buy	1.29	23,000	29,755	333,118	Dec 15 06:00 AM

Open in Screener

TARA

Protara Therapeutics Inc

Dec 08 • 04:00PM ET

1.60

Dollar change +0.23
Percentage change 16.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

TARA Protara Therapeutics Inc daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-6.13	Insider Own	25.64%	Shs Outstand	11.27M	Perf Week	11.50%
Market Cap	18.18M	Forward P/E	-	EPS next Y	-3.84	Insider Trans	0.00%	Shs Float	8.45M	Perf Month	34.45%
Income	-69.17M	PEG	-	EPS next Q	-0.92	Inst Own	37.02%	Short Float / Ratio	0.57% / 1.37	Perf Quarter	-24.53%
Sales	0.00M	P/S	-	EPS this Y	39.04%	Inst Trans	-4.78%	Short Interest	0.05M	Perf Half Y	-42.24%
Book/sh	6.77	P/B	0.24	EPS next Y	-7.50%	ROA	-58.35%	Target Price	30.60	Perf Year	-53.35%
Cash/sh	6.52	P/C	0.25	EPS next 5Y	-	ROE	-64.00%	52W Range	1.04 - 4.18	Perf YTD	-40.30%
Dividend	-	P/FCF	-	EPS past 5Y	41.46%	ROI	-84.67%	52W High	-61.72%	Beta	1.49
Dividend %	-	Quick Ratio	11.49	Sales past 5Y	0.00%	Gross Margin	-	52W Low	53.85%	ATR	0.13
Employees	25	Current Ratio	11.49	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	66.22	Volatility	8.74% 9.37%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	-27.27%	Profit Margin	-	Rel Volume	2.24	Prev Close	1.37
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Nov 03 BMO	Payout	-	Avg Volume	35.20K	Price	1.60
Recom	1.00	SMA20	25.29%	SMA50	14.08%	SMA200	-34.55%	Volume	78,954	Change	16.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
07:30AM	Loading…
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
08:00AM	Loading…
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)
05:50AM	Loading…
Mar-08-22 05:50AM	Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year (Simply Wall St.)
Mar-02-22 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.67%
Feb-01-22 08:00AM	Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) +8.25%
Jan-10-22 08:00AM	Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-04-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-08-21 11:15AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-04-21 08:00AM	Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Oct-25-21 04:45PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-21 07:00AM	Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +11.85%
Sep-17-21 04:05PM	Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-13-21 07:00AM	Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
Sep-09-21 10:31AM	A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders (Simply Wall St.)
Sep-07-21 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 08:00AM	Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Jul-07-21 08:00AM	Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Jun-22-21 07:30AM	ProBility Media Provides Corporate Update (PR Newswire)
Jun-10-21 08:00AM	Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors (GlobeNewswire)
May-13-21 08:00AM	Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
May-06-21 07:30AM	Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview (GlobeNewswire) -5.69%
Apr-23-21 07:00AM	Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) -18.41%
Apr-19-21 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks)
Mar-30-21 07:01AM	Do Insiders Own Lots Of Shares In Protara Therapeutics, Inc. (NASDAQ:TARA)? (Simply Wall St.)
Mar-11-21 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview (GlobeNewswire) +6.40%
Mar-10-21 08:00AM	Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-04-21 08:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-02-21 08:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors (GlobeNewswire)
Dec-16-20 11:07PM	Is TARA A Good Stock To Buy Now? (Insider Monkey)
Dec-07-20 04:30PM	Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer (GlobeNewswire)
Dec-03-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-20 07:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-12-20 07:15AM	Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Nov-11-20 07:00AM	Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
Nov-04-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-20 03:12PM	What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry? (Simply Wall St.)
Sep-22-20 08:13AM	Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire)
Sep-21-20 04:01PM	Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -7.97%
Sep-08-20 07:00AM	Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications (GlobeNewswire) -6.09%
Sep-02-20 05:49PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-20 07:00AM	Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Jul-28-20 07:00AM	Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) +5.29%
Jul-24-20 07:00AM	Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors (GlobeNewswire)
Jul-03-20 06:34PM	Hedge Funds Have Never Been This Bullish On Protara Therapeutics, Inc. (TARA) (Insider Monkey)
Jul-02-20 07:59PM	CORRECTION Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-20 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.74%
May-26-20 08:30AM	Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease (GlobeNewswire) +13.98%
May-13-20 08:00AM	Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview (GlobeNewswire) -8.46%
May-11-20 08:38AM	ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics (GlobeNewswire)
May-05-20 04:05PM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-20 07:00AM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-20 08:00AM	ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Open in Screener

TELA

TELA Bio Inc

Dec 08 • 04:00PM ET

5.54

Dollar change +0.11
Percentage change 2.03	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Index	RUT	P/E	-	EPS (ttm)	-2.06	Insider Own	30.50%	Shs Outstand	19.17M	Perf Week	-1.77%
Market Cap	135.67M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	0.32%	Shs Float	17.02M	Perf Month	-4.48%
Income	-43.75M	PEG	-	EPS next Q	-0.42	Inst Own	62.62%	Short Float / Ratio	4.24% / 4.58	Perf Quarter	-37.89%
Sales	53.08M	P/S	2.56	EPS this Y	29.49%	Inst Trans	17.69%	Short Interest	0.72M	Perf Half Y	-49.91%
Book/sh	1.25	P/B	4.44	EPS next Y	20.75%	ROA	-52.44%	Target Price	14.40	Perf Year	-42.17%
Cash/sh	2.38	P/C	2.33	EPS next 5Y	-	ROE	-162.49%	52W Range	4.23 - 13.18	Perf YTD	-51.83%
Dividend	-	P/FCF	-	EPS past 5Y	-2.37%	ROI	-61.70%	52W High	-57.97%	Beta	0.93
Dividend %	-	Quick Ratio	4.43	Sales past 5Y	60.37%	Gross Margin	69.08%	52W Low	30.82%	ATR	0.33
Employees	173	Current Ratio	5.36	Sales Q/Q	34.89%	Oper. Margin	-77.69%	RSI (14)	52.35	Volatility	6.47% 6.54%
Optionable	Yes	Debt/Eq	1.33	EPS Q/Q	30.00%	Profit Margin	-82.43%	Rel Volume	0.61	Prev Close	5.43
Shortable	Yes	LT Debt/Eq	1.32	Earnings	Nov 09 AMC	Payout	-	Avg Volume	157.56K	Price	5.54
Recom	1.00	SMA20	9.57%	SMA50	-5.00%	SMA200	-37.66%	Volume	96,233	Change	2.03%

Date	Action	Analyst	Rating Change	Price Target Change
May-31-22	Initiated	Lake Street	Buy	$17
Dec-03-19	Initiated	Piper Jaffray	Overweight
Dec-03-19	Initiated	JMP Securities	Mkt Outperform
Dec-03-19	Initiated	Jefferies	Buy
Dec-03-19	Initiated	Canaccord Genuity	Buy

Dec-05-23 07:00AM	TELA Bio to Take Part in Connecting the Dots (GlobeNewswire) -6.68%
Nov-16-23 07:00AM	TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference (GlobeNewswire)
Nov-12-23 12:20PM	TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.37%
Nov-09-23 04:05PM	TELA Bio Reports Third Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Loading…
Oct-26-23 07:00AM	TELA Bio to Announce Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-18-23 04:05PM	TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-16-23 07:00AM	TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery (GlobeNewswire)
Aug-11-23 10:03AM	TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:18AM	Q2 2023 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-09-23 06:05PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:03PM	TELA Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:02PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-26-23 07:00AM	TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-06-23 10:09AM	Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains? (Zacks)
07:51PM	Loading…
Jun-18-23 07:51PM	Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength? (Zacks)
Jun-15-23 07:00AM	New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options (GlobeNewswire) -7.05%
May-25-23 07:00AM	TELA Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-23 10:30AM	What You Can Learn From TELA Bio, Inc.'s (NASDAQ:TELA) P/S (Simply Wall St.)
May-19-23 07:00AM	TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab (GlobeNewswire)
May-12-23 07:44AM	Q1 2023 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:25PM	TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:02PM	TELA Bio Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:00AM	TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference (GlobeNewswire)
May-08-23 04:30PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 07:00AM	TELA Bio to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-30-23 08:26AM	TELA Bio, Inc. (NASDAQ:TELA) stock most popular amongst private equity firms who own 36%, while individual investors hold 26% (Simply Wall St.)
Apr-28-23 06:47PM	Dlocal, Augmedix See Activist Investor Action (Barrons.com)
06:47PM	Dlocal and Augmedix Stock See Action From Activist Investors (Barrons.com)
Apr-27-23 07:00AM	TELA Bio to Announce First Quarter 2023 Financial Results (GlobeNewswire)
11:00PM	Loading…
Apr-18-23 11:00PM	TELA Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	TELA Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-03-23 06:14AM	TELA Bio's (NASDAQ:TELA) investors will be pleased with their notable 34% return over the last three years (Simply Wall St.)
Mar-29-23 07:00AM	TELA Bios OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023 (GlobeNewswire)
Mar-24-23 07:15AM	TELA Bio, Inc. (NASDAQ:TELA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 07:00AM	TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery (GlobeNewswire)
Mar-22-23 06:01AM	Q4 2022 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents) -5.91%
Mar-21-23 05:15PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:02PM	TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-16-23 07:00AM	TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications (GlobeNewswire) +5.74%
Feb-28-23 07:00AM	TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-24-23 04:02PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.05%
Feb-21-23 07:00AM	TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques (GlobeNewswire)
Feb-14-23 07:00AM	TELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization (GlobeNewswire)
Jan-20-23 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 07:00AM	TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds (GlobeNewswire)
Dec-23-22 05:46AM	One TELA Bio, Inc. (NASDAQ:TELA) insider upped their stake by 342% in the previous year (Simply Wall St.)
Dec-21-22 07:00AM	TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-22 04:02PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-22 07:00AM	TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-12-22 07:42AM	TELA Bio Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 05:25PM	TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -8.71%
04:01PM	TELA Bio Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 07:00AM	TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire) -7.19%
Oct-28-22 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-27-22 07:00AM	TELA Bio to Announce Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 07:00AM	TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair (GlobeNewswire)
Oct-24-22 10:24AM	The past year for TELA Bio (NASDAQ:TELA) investors has not been profitable (Simply Wall St.)
Sep-01-22 07:00AM	TELA Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-22 04:01PM	TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-19-22 10:52AM	Lab Notes: Larimar readying response to the FDA's clinical hold; Tela Bio completes $36.8M stock sale (American City Business Journals)
Aug-18-22 04:01PM	TELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Aug-16-22 12:01PM	Tela Bio prices $32M public stock offering; share price drops (American City Business Journals) -11.15%
Aug-15-22 10:20PM	TELA Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	TELA Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-10-22 10:30PM	TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript (Motley Fool)
05:35PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TELA Bio Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-05-22 07:00AM	TELA Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-04-22 07:00AM	TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting (GlobeNewswire)
Jul-29-22 04:01PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-27-22 07:00AM	TELA Bio to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-20-22 07:00AM	TELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc. (GlobeNewswire)
Jul-08-22 06:45AM	Is TELA Bio, Inc. (NASDAQ:TELA) Popular Amongst Institutions? (Simply Wall St.)
Jun-24-22 08:52AM	uniQure (QURE) Moves 27% Higher: Will This Strength Last? (Zacks)
Jun-23-22 11:02AM	TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar? (Zacks) +7.08%
Jun-10-22 06:15AM	Trade Alert: The CFO & COO Of TELA Bio, Inc. (NASDAQ:TELA), Roberto Cuca, Has Just Spent US$83k Buying 342% More Shares (Simply Wall St.) -8.15%
Jun-02-22 07:00AM	TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference (GlobeNewswire)
May-31-22 07:00AM	TELA Bio Secures Up to $50 Million in Debt Financing from MidCap Financial (GlobeNewswire) -5.03%
May-26-22 07:00AM	TELA Bio to Participate in Upcoming Jefferies Healthcare Conference (GlobeNewswire) +6.22%
May-17-22 08:25AM	The past year for TELA Bio (NASDAQ:TELA) investors has not been profitable (Simply Wall St.)
May-10-22 05:45PM	TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TELA Bio Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-09-22 07:00AM	TELA Bio to Participate in Upcoming 2022 H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
May-05-22 05:55PM	Guardant Health (GH) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-02-22 04:11AM	Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength? (Zacks)
Apr-29-22 05:00PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-22 07:00AM	TELA Bio to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 07:00AM	TELA Bio Appoints D. Taylor Ocasio as General Counsel (GlobeNewswire) -5.00%
Mar-30-22 07:00AM	TELA Bio to Participate in Upcoming Needham & Co. 21st Annual Healthcare Virtual Conference (GlobeNewswire)
Mar-21-22 05:15PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-16-22 07:00AM	TELA Bio to Participate in Upcoming Canaccord Genuity Musculoskeletal Conference in Chicago, IL (GlobeNewswire)
Mar-08-22 12:42PM	Tela Bio begins transformation with plans for new products and hiring (American City Business Journals)
09:21AM	Is TELA Bio (NASDAQ:TELA) A Risky Investment? (Simply Wall St.)
Mar-07-22 04:01PM	TELA Bio to Announce Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-03-22 08:35AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TELA Bio Announces U.S. Commercial Launch of SiteGuard No Rinse Antimicrobial Solution (GlobeNewswire)
Feb-28-22 05:45PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-25-22 04:01PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Firestone Gregory A.	Chief Business Officer	Dec 05	Buy	5.65	2,600	14,688	35,511	Dec 07 04:02 PM
KOBLISH ANTONY	Chief Executive Officer	Nov 14	Buy	4.54	11,000	49,976	303,634	Nov 14 08:01 PM
Cuca Roberto	COO and CFO	Nov 14	Buy	4.49	10,000	44,938	62,371	Nov 14 08:02 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 21	Sale	9.41	27,700	260,657	2,835,542	Apr 21 05:08 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 20	Sale	9.43	28,300	266,869	2,863,242	Apr 21 05:08 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 19	Sale	9.30	136,000	1,264,800	2,891,542	Apr 21 05:08 PM
Burgess Vincent J	Director	Mar 29	Option Exercise	4.44	4,860	21,578	7,995	Mar 31 04:32 PM

Open in Screener

ETON

Eton Pharmaceuticals Inc

Dec 08 • 04:00PM ET

3.60

Dollar change -0.03
Percentage change -0.83	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

ETON Eton Pharmaceuticals Inc daily Stock Chart

Index	-	P/E	42.50	EPS (ttm)	0.08	Insider Own	12.69%	Shs Outstand	25.35M	Perf Week	-2.70%
Market Cap	92.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	22.40M	Perf Month	-19.10%
Income	2.23M	PEG	-	EPS next Q	-	Inst Own	26.89%	Short Float / Ratio	3.36% / 5.90	Perf Quarter	-30.64%
Sales	32.83M	P/S	2.81	EPS this Y	-	Inst Trans	6.66%	Short Interest	0.75M	Perf Half Y	-6.98%
Book/sh	0.66	P/B	5.47	EPS next Y	-	ROA	8.42%	Target Price	10.00	Perf Year	22.03%
Cash/sh	0.86	P/C	4.19	EPS next 5Y	-	ROE	15.90%	52W Range	2.42 - 5.81	Perf YTD	27.66%
Dividend	-	P/FCF	9.98	EPS past 5Y	6.23%	ROI	10.56%	52W High	-38.04%	Beta	1.16
Dividend %	-	Quick Ratio	2.51	Sales past 5Y	11156.18%	Gross Margin	72.47%	52W Low	48.76%	ATR	0.20
Employees	28	Current Ratio	2.61	Sales Q/Q	118.33%	Oper. Margin	5.68%	RSI (14)	43.47	Volatility	4.12% 5.89%
Optionable	Yes	Debt/Eq	0.35	EPS Q/Q	81.25%	Profit Margin	6.80%	Rel Volume	0.09	Prev Close	3.63
Shortable	Yes	LT Debt/Eq	0.25	Earnings	Nov 09 AMC	Payout	-	Avg Volume	127.79K	Price	3.60
Recom	1.00	SMA20	-2.25%	SMA50	-7.86%	SMA200	-5.71%	Volume	11,525	Change	-0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-21	Resumed	B. Riley Securities	Buy	$10
Jan-04-21	Reiterated	H.C. Wainwright	Buy	$20 → $15
Sep-20-19	Initiated	B. Riley FBR	Buy	$13.50
Jun-10-19	Initiated	H.C. Wainwright	Buy	$15

Nov-11-23 11:09AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:01PM	Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-30-23 06:50AM	Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Oct-23-23 05:16AM	Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-18-23 08:00AM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (PR Newswire)
06:50AM	Loading…
Oct-04-23 06:50AM	Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone (GlobeNewswire)
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-20-23 09:40AM	Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-12-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Eton Pharmaceuticals, Inc. (ETON) (Zacks)
Aug-25-23 11:36AM	Eton Pharmaceuticals (ETON): A Modestly Undervalued Stock Worth Your Attention (GuruFocus.com)
Aug-23-23 06:50AM	Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-16-23 09:15AM	Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run? (Zacks) -8.44%
Aug-13-23 07:52AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 12:44PM	Q2 2023 Eton Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +38.08%
Aug-10-23 05:40PM	Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-08-23 10:50AM	Techne (TECH) Meets Q4 Earnings Estimates (Zacks)
Aug-01-23 04:05PM	Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-17-23 04:05PM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (PR Newswire)
Jul-15-23 08:40AM	The past three years for Eton Pharmaceuticals (NASDAQ:ETON) investors has not been profitable (Simply Wall St.)
Jun-28-23 06:50AM	Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection (GlobeNewswire) -17.33%
May-16-23 11:35AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 05:35PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 06:50AM	Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution) (GlobeNewswire)
May-03-23 04:05PM	Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire)
Apr-19-23 11:22AM	Getting In Cheap On Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Might Be Difficult (Simply Wall St.)
Mar-22-23 07:17AM	When Will Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Breakeven? (Simply Wall St.)
Mar-18-23 02:03AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 05:25PM	Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass Estimates (Zacks) +7.89%
04:01PM	Loading…
04:01PM	Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results (GlobeNewswire)
Mar-15-23 06:50AM	Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 (GlobeNewswire)
Mar-07-23 04:05PM	Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023 (GlobeNewswire)
Feb-08-23 12:00PM	Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Feb-05-23 07:30AM	Shareholders in Eton Pharmaceuticals (NASDAQ:ETON) are in the red if they invested three years ago (Simply Wall St.)
Jan-31-23 08:00AM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements (PR Newswire)
Jan-25-23 10:00AM	Best Momentum Stocks to Buy for January 25th (Zacks)
07:21AM	New Strong Buy Stocks for January 25th (Zacks)
Jan-24-23 12:26PM	Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic (Zacks)
Jan-23-23 11:01AM	Amarin Corporation (AMRN) Down 13% in One Week: Here's Why (Zacks)
10:00AM	Best Momentum Stocks to Buy for January 23rd (Zacks)
07:36AM	New Strong Buy Stocks for January 23rd (Zacks)
Jan-12-23 10:34AM	ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection (Zacks) -5.41%
Jan-11-23 07:27AM	Etons stock rallies as FDA reviews treatment for alcohol poisoning (MarketWatch) +13.85%
06:50AM	Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection (GlobeNewswire)
Nov-23-22 12:37PM	Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation (Zacks)
Nov-22-22 12:45PM	bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals (Zacks)
Nov-16-22 10:33AM	Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study (Zacks)
05:34AM	Eton Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 05:45PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of ETON.OQ earnings conference call or presentation 10-Nov-22 9:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 04:05PM	Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (GlobeNewswire)
Oct-18-22 04:05PM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements (PR Newswire)
06:50AM	Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference (GlobeNewswire)
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE)
Sep-13-22 09:00AM	Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution (GlobeNewswire)
Aug-30-22 04:05PM	Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 05:35PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 10:00AM	Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-04-22 10:00AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy? (Zacks)
Aug-02-22 08:00AM	Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022 (GlobeNewswire)
Jul-18-22 08:09AM	Eton's stock gains 16% after announcing FDA approval of epilepsy drug (MarketWatch) +8.60%
07:05AM	Eton Pharmaceuticals Announces FDA Approval of ZONISADE (Zonisamide Oral Suspension) (GlobeNewswire)
Jun-24-22 09:45AM	Eton Pharma Shares Tick Higher After Offloading Hospital Products (Benzinga)
07:30AM	Eton Pharmaceuticals Announces Sale of Hospital Products (GlobeNewswire)
Jun-13-22 12:28PM	Eton Pharmaceuticals (NASDAQ:ETON) shareholders have endured a 62% loss from investing in the stock three years ago (Simply Wall St.)
May-13-22 09:08AM	Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Profit Outlook (Simply Wall St.) +7.61%
May-12-22 05:15PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.86%
04:02PM	Eton Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-10-22 05:45PM	Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-22 07:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
03:00PM	Analysts Estimate Eton Pharmaceuticals, Inc. (ETON) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-03-22 04:02PM	Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 (GlobeNewswire)
09:15AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-12-22 10:03AM	Analysts Just Published A Bright New Outlook For Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) (Simply Wall St.)
Apr-11-22 04:01PM	Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer (GlobeNewswire) -10.35%
07:30AM	Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection (GlobeNewswire)
Mar-16-22 04:02PM	Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results (GlobeNewswire)
Mar-14-22 07:00AM	Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL) (GlobeNewswire)
Mar-10-22 05:25PM	Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates (Zacks)
Mar-08-22 08:00AM	Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022 (GlobeNewswire)
Jan-10-22 05:19AM	Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Dec-20-21 07:30AM	Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid) (GlobeNewswire)
Nov-26-21 04:43AM	Eton Pharmaceuticals (NASDAQ:ETON) shareholders have endured a 42% loss from investing in the stock a year ago (Simply Wall St.)
Nov-18-21 02:04PM	Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director (GlobeNewswire)
Nov-15-21 06:45PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Eton Pharmaceuticals Reports Third Quarter Financial Results (GlobeNewswire)
06:30AM	Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE® (GlobeNewswire)
Nov-08-21 08:29AM	FDA Approves Eton's Formulated Topiramate For Seizure, Migraine Treatment (Benzinga) -10.65%
06:00AM	Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA (topiramate) Oral Solution (GlobeNewswire)
Nov-04-21 03:01PM	Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-21 04:15PM	Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021 (GlobeNewswire)
Oct-28-21 07:30AM	Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid (GlobeNewswire)
Oct-12-21 07:14AM	Loss-Making Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Set To Breakeven (Simply Wall St.)
Aug-16-21 05:25PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:02PM	Eton Pharmaceuticals Reports Second Quarter Financial Results (GlobeNewswire)
Aug-04-21 03:00PM	Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Aug-03-21 04:05PM	Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021 (GlobeNewswire)

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

HROW

Harrow Inc

TCON

TRACON Pharmaceuticals Inc

TARA

Protara Therapeutics Inc

TELA

TELA Bio Inc

ETON

Eton Pharmaceuticals Inc

Upgrade your FINVIZ experience